| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1947 |
| Trial ID | NCT03628053 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Kymriah|Tisagenlecleucel |
| Generation | 2nd |
| Phase | Phase3 |
| Recruitment status | Withdrawn |
| Title | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia |
| Year | 2018 |
| Country | Switzerland |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CCTL019I2301 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||